BillionToOne, a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all, announces the closure of an oversubscribed Series C funding round of $125 million.

This round was co-led by incoming investor Adams Street Partners and existing investor Hummingbird Ventures with significant participation from Baillie Gifford, Neotribe Ventures, Norwest Venture Partners, Civilization Ventures, Fifty Years VC, Pacific 8 Ventures, Time BioVentures, and Libertus Capital, among others.